Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ajax Therapeutics Inc.
Headquarters: New York, United States of America
Website: https://www.ajaxtherapeutic...
Year Founded: 2019
Status: Private
BioCentury | May 16, 2024
Finance
Venture Report: Blackstone eyes pipeline-in-a-product via Uniquity launch
Plus: New funds for Sands and NewVale, and series C rounds for Lycia and Ajax
BioCentury | Aug 23, 2023
Management Tracks
Mirati CFO Stelzer to depart
Plus: Peterson joins Exelixis, Eckhardt expands role at Bayer and updates from Alpine, Neuron23, Ajax
BioCentury | Mar 10, 2023
Management Tracks
Drachman leaving Neoleukin amid restructuring
Plus: Aspesi to lead HR at Editas and updates from Homology, GlycoMimetics and Ajax
BioCentury | Sep 29, 2021
Management Tracks
Rawat becomes president, CBO at Fusion
Plus: Sporos, Ajax, Nanocan and NeuroSense
BioCentury | Jun 4, 2021
Finance
June 3 Quick Takes: venBio’s new $550M fund, plus Innovent-AnHeart, Ajax, Scynexis and more
Just 15 months after closing its $394 million third fund, venBio has completed its $550 million Global Strategic Fund IV, a vehicle designed to invest in 12-15 start-ups and in some cases provide
Items per page:
1 - 5 of 5